News
GALNF
--
NaN%
--
UBS Keeps Their Sell Rating on Galenica AG (GALE)
TipRanks · 03/17 09:45
Galenica’s Bichsel Unit to Shut Drug Production, Cut 152 Jobs by 2026
TipRanks · 03/12 07:00
Galenica AG (GALE) Gets a Sell from UBS
TipRanks · 03/11 09:46
Galenica lifts earnings, boosts dividend and raises mid‑term profit targets
TipRanks · 03/10 06:03
Galenica to Close Bichsel Drug Production and Pivot to Home Care
TipRanks · 02/24 06:04
UBS Keeps Their Hold Rating on Galenica AG (GALE)
TipRanks · 02/13 12:37
Galenica tops CHF 4 billion in sales as integrated healthcare network drives record growth
TipRanks · 01/22 06:02
UBS Gives a Hold Rating to Galenica AG (GALE)
TipRanks · 01/15 11:57
Galenica Expands Digital Presence with Puravita Stake Increase
TipRanks · 12/16/2025 13:33
Galenica AG (GALE) Gets a Hold from UBS
TipRanks · 12/12/2025 12:06
East 72 Dynasty Trust Q2 2025 Quarterly Report
Seeking Alpha · 07/10/2025 12:58
More
Webull provides a variety of real-time GALNF stock news. You can receive the latest news about Galencia through multiple platforms. This information may help you make smarter investment decisions.
About GALNF
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.